background


Product Information:

ARQ-087

Derazantinib (ARQ-087) is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.

Cat. No.: EX-A1717    Purity: >98%
ARQ-087
For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
100mg585In-stock
200mg885In-stock
500mg1350In-stock
1g1950In-stock
5g6885In-stock
10g9885In-stock


SynonymsDerazantinib
CAS No.1234356-69-4
Purity>98%
FormulaC29H29FN4O
Mol Weight468.5652
AppearanceSolid powder
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
 
 
Reference:  

[1]. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594.

[2]. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66

CoACoA of ARQ-087
Smiles:COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C4=CC=CC=C4C3=N2)=CC=C1

KEYWORDS: buy ARQ-087 | ARQ-087 supplier | purchase | cost | manufacturer | order | distributor | buy 1234356-69-4 | 1234356-69-4 supplier